期刊文献+

新建ICU病原菌分布及耐药性调查分析 被引量:5

Analysis of distribution and drug-resistance of pathogens in a new intensive care unit
原文传递
导出
摘要 目的了解新建ICU启用后患者医院感染状况,探讨其流行菌株及细菌耐药性,为ICU经验性抗感染治疗提供科学依据。方法对2009年8月23日-2010年8月22日入住新建ICU时间>48h患者的各种体液标本进行培养,分离病原菌,进行耐药性分析。结果新建ICU患者医院感染率为72.6%;所有病原菌中,革兰阴性菌占78.5%,其中鲍氏不动杆菌占23.6%,铜绿假单胞菌占20.8%,洋葱伯克霍尔德菌占18.7%,革兰阳性菌占5.5%,真菌占16.0%,真菌以白色假丝酵母菌为主;鲍氏不动杆菌除对头孢哌酮/舒巴坦耐药率为38.2%外,对其他抗菌药物耐药率均>79.0%;金黄色葡萄球菌和表皮葡萄球菌均对青霉素类耐药,对万古霉素、替考拉宁及利奈唑胺敏感,敏感率>90.0%。结论革兰阴性菌是新建ICU患者医院感染的主要致病菌,ICU医院感染的治疗首先需覆盖革兰阴性菌,根据药敏分析,头孢哌酮/舒巴坦可作为经验性治疗的首选;若考虑存在假丝酵母菌属感染,氟康唑可作为首选。 OBJECTIVE To investigate the epidemiology of hospital infection,distribution and drug resistance of pathogens in the new intensive care unit(ICU).METHODS Different fluid samples were collected from critically ill patients who stayed in the new ICU for more than 48 hours from August 2009 to August 2010.The distribution and drug-resistance of pathogens were analyzed.RESULTS The incidence of nosocomial infection is 64.5% in the new ICU.The main pathogens consisted of gram-negative bacteria(78.5%),gram-positive bacteria(5.5%),fungi(16.0%).The top 3 gram-negative pathogens were Acinetobacter baumannii(23.61%),Pseudomonas aeruginosa(20.83%) and Burkholderia cepacia(18.75%).Camdida albican is the main Fungi,which is susceptibility to fluconazol.CONCLUSION Gram-negative bacteria are the main pathogens in new ICU,empiric antibiotic therapy should focus on them.Sulperazon could be the first choice according to drug susceptibility,and fluconazol could be chose empirically once invasive fungal infection is suspected.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2012年第4期867-869,共3页 Chinese Journal of Nosocomiology
关键词 重症监护病房 医院感染 病原菌 Intensive care unit Nosocomial infections Pathogen
  • 相关文献

参考文献8

二级参考文献51

共引文献699

同被引文献49

  • 1吴安华,任南,文细毛,易霞云,黄勋,徐秀华.159所医院医院感染现患率调查结果与分析[J].中国感染控制杂志,2005,4(1):12-16. 被引量:202
  • 2李双玲,王东信,吴新民,蒋洪.外科重症监护病房医院感染和相关死亡危险因素[J].中华医院感染学杂志,2006,16(5):503-507. 被引量:84
  • 3李影林.中华医学检验全书[M].北京:人民卫生出版社,1996.357.
  • 4王羽,主编.医院感染管理办法[M].北京:中国法制出版社,2006:156-178.
  • 5Falagas ME, Karveli EA. The changing global epide- miology of Acinetobacter baumannii infections: adevel- opment with major public health implications[J]. Clin Microbiol Infect, 2007, 13(2): 117-119.
  • 6Ansaldi F, Canepa P, Bassetti M, et al. Sequential outbreaks of multidrug-resistant Acinetobacter baurnan- nil in intensive care units of a tertiary referral hospital in Italy: combined molecular approach for epidemiologi- cal investigation[J]. J Hosp Infect, 2011, 79(2): 134- 140.
  • 7Romanelli RM, Jesus LA, Clemente WT, et al. Out- break of resistant Acinetobacter baumannii- measures and proposal for prevention and control[J]. Braz J In- fect Dis, 2009, 13(5): 341-347.
  • 8Berlau J, Aucken H, Malnick H, et al. Distribution of Acinetobacter species on skin of healthy humans[J]. EurJ Clin Microbiol Infect Dis, 1999, 18(3): 179- 183.
  • 9Pogue JM, Mann T, Barber KE, et al. Carbapenem- resistant Acinetobacter baumannii: epidemiology, sur- veillance and management[J]. Expert Rev Anti Infect Ther, 2013, 11(4): 383-393.
  • 10Zheng YL, Wan YF, Zhou LY, et al. Risk factors and mortality of patients with nosocomial carbapenem-re- sistant Acinetobacter baurnannii pneumonia[J]. Am J Infect Control, 2013, 41(7): e59-e63.

引证文献5

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部